课题基金 / 基金详情

Development and translation of a novel radioligand to measure pathological changes in glucocorticoid receptor expression in the brain

Development and translation of a novel radioligand to measure pathological changes in glucocorticoid receptor expression in the brain
开发和翻译一种新型放射性配体,用于测量大脑中糖皮质激素受体表达的病理变化
批准号:
9427881
负责人:
Michael John Evans
金额:
$69.08万
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-12-01 至 2020-11-30

项目摘要

项目成果

Michael John Evans的其他基金

相似基金

相关文献

中文摘要
翻译
项目摘要 本课题的目的是研制一种靶向糖皮质激素受体(GR)的脑渗透性放射性配体。 在具体目标1中,对GR具有亚纳摩尔亲和力的非甾体配体将被放射性氟化,并且其 将在体外评估药理学。将在小鼠体内测定GR的特异性结合, 具体目标2.还将计算eIND申请的大鼠剂量测定估计值和毒性。在特定 第三,将进行首次人体研究,以确定人体剂量。该项目的数据将 赋予社区一个新的翻译成像工具,研究GR表达变化的作用, 严重的情绪障碍比如抑郁症
英文摘要
Project Abstract The goal of this project is to develop a brain permeable radioligand targeting the glucocorticoid receptor (GR). A non-steroidal ligand with sub-nanomolar affinity for GR will be radiofluorinated in specific aim 1, and its pharmacology will be assessed in vitro. Specific binding for GR will be determined in vivo in mice during specific aim 2. Rat dosimetry estimates and toxicity will also be calculated for an eIND application. In specific aim 3, a first in man study will be conducted to determine human dosimetry. The data from this project will confer upon the community a new translational imaging tool to study the role of GR expression changes in severe mood disorders like depression.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Developing a pretargeting strategy to detect Fe(II) for nuclear medicine applications
Developing a pretargeting strategy to detect Fe(II) for nuclear medicine applications
Developing a pretargeting strategy to detect Fe(II) for nuclear medicine applications
Development of a translational imaging tool as a predictive biomarker for anti-PD-1/PD-L1 immunotherapies
海外基金